Treatment	O
for	O
patients	O
with	O
diabetes	O

It	O
is	O
notable	O
that	O
treatment	O
of	O
diabetes	O
has	O
not	O
been	O
directly	O
monitored	O
by	O
OECD	O
indicators	O
,	O
largely	O
due	O
to	O
complexity	O
in	O
data	O
collection	O
.	O

Treatment	O
is	O
tailored	O
for	O
individuals	O
depending	O
on	O
the	O
patient	O
'	O
s	O
disease	O
status	O
,	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
diabetes	O
management	O
.	O

Clinical	O
trials	O
have	O
found	O
that	O
a	O
one	O
percentage	O
point	O
reduction	O
in	O
HbA1c	O
levels	O
would	O
reduce	O
micro	O
-	O
vascular	B-Multi-tissue_structure
complications	O
by	O
25	O
%	O
to	O
30	O
%	O
[	O
49	O
,	O
50	O
]	O
and	O
a	O
10	O
mmHg	O
reduction	O
in	O
blood	B-Organism_substance
pressure	O
would	O
decrease	O
macro	O
-	O
and	O
micro	O
-	O
vascular	B-Multi-tissue_structure
complications	O
and	O
death	O
rates	O
by	O
32	O
%	O
[	O
51	O
]	O
.	O

Improved	O
control	O
of	O
blood	B-Organism_substance
lipids	O
can	O
reduce	O
risk	O
of	O
coronary	B-Multi-tissue_structure
heart	B-Organ
disease	O
by	O
39	O
%	O
and	O
risk	O
of	O
death	O
by	O
43	O
%	O
[	O
52	O
]	O
.	O

RAND	O
'	O
s	O
Quality	O
Assessment	O
Tools	O
System	O
offers	O
indicators	O
relating	O
to	O
diabetes	O
treatment	O
[	O
53	O
]	O
,	O
and	O
application	O
of	O
these	O
indicators	O
in	O
a	O
national	O
study	O
in	O
the	O
US	O
has	O
provided	O
insight	O
into	O
adherence	O
to	O
recommended	O
treatment	O
regimens	O
.	O

For	O
people	O
with	O
newly	O
diagnosed	O
diabetes	O
56	O
%	O
received	O
dietary	O
and	O
exercise	O
counselling	O
.	O

In	O
type	O
2	O
diabetes	O
patients	O
,	O
use	O
of	O
oral	B-Organism_subdivision
hypoglycaemic	O
agents	O
for	O
those	O
inadequately	O
controlled	O
on	O
dietary	O
therapy	O
was	O
38	O
%	O
and	O
use	O
of	O
insulin	O
for	O
those	O
inadequately	O
controlled	O
on	O
oral	B-Organism_subdivision
hypoglycaemics	O
was	O
39	O
%	O
.	O

Fifty	O
-	O
five	O
percent	O
of	O
diabetics	O
were	O
offered	O
an	O
ACE	O
inhibitor	O
within	O
3	O
months	O
of	O
the	O
notation	O
of	O
proteinuria	B-Organism_substance
unless	O
contraindicated	O
.	O

The	O
AusDiab	O
study	O
reported	O
the	O
treatment	O
pattern	O
among	O
Australian	O
adults	O
with	O
type	O
2	O
diabetes	O
[	O
37	O
]	O
.	O

While	O
32	O
%	O
of	O
diabetes	O
patients	O
were	O
on	O
diet	O
regimen	O
only	O
,	O
58	O
%	O
used	O
oral	B-Organism_subdivision
hypoglycaemic	O
agents	O
and	O
diet	O
only	O
,	O
and	O
another	O
10	O
%	O
took	O
insulin	O
.	O

Bailie	O
and	O
colleagues	O
reported	O
pharmaceutical	O
interventions	O
for	O
diabetes	O
patients	O
in	O
remote	O
Aboriginal	O
communities	O
in	O
the	O
Northern	O
Territory	O
[	O
54	O
]	O
.	O

During	O
the	O
3	O
-	O
years	O
study	O
period	O
,	O
75	O
-	O
79	O
%	O
of	O
Aboriginal	O
patients	O
took	O
oral	B-Organism_subdivision
hypoglycaemic	O
agents	O
,	O
and	O
4	O
-	O
7	O
%	O
used	O
insulin	O
.	O

